At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 130 enrolled
Drug / intervention
Bepreve (bepotastine besilate ophthalmic solution) 1.5% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
In Brief
A Phase 3 clinical trial evaluating Bepreve (bepotastine besilate ophthalmic solution) 1.5%, placebo comparator, and 1 other intervention for Allergic Conjunctivitis. Completed, enrolled 130 participants across 1 site.
Detailed Summary
Efficacy and safety study of bepotastine besilate ophthalmic solution in allergic conjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedJan 2008
Primary CompletionJun 2008
TodayJul 2026
First PostedJan 4, 2008
Enrollment StartOct 1, 2007
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.5 years ago
Interventions
Bepreve (bepotastine besilate ophthalmic solution) 1.5%drug
sterile ophthalmic solution
placebo comparatordrug
sterile ophthalmic solution
Bepotastine Besilate Ophthalmic Solution 1.0%drug
sterile ophthalmic solution